MZ
Mahkam Zanganeh (Co-Chief Executive Officer) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Summit Therapeutics Inc. (SMMT). Across 2 priced purchase filings, the average 21-session return was +12.9% from execution and +12.9% from disclosure (delay-adjusted; derived). The largest single filing was $50.0M of SMMT (3,810,000 sh × $13.12, as filed), executed Jun 12. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+12.9%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+12.9%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$51.4M
shares × price, as filed
Last traded
Jun 12
Filed Jun 12
Median ADV $66.4M across their filed names
Open performance→Volume by month
Buys $57.8M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
SMMT
Summit Therapeutics Inc.
SMMT · 4 buys · 0 sells
4 filings
Recent filings
SMMTPURCHASE
Summit Therapeutics Inc.
View filing →
$50.0M3,810,000 sh × $13.12
Exec Jun 12
Filed Jun 12 · 2:35 PM ET SMMTPURCHASE Summit Therapeutics Inc. View filing → $1.5M
100,000 sh × $14.60
Exec Jun 4
Filed Jun 4 · 5:45 PM ET SMMTPURCHASE Summit Therapeutics Inc. View filing → $500K
26,680 sh × $18.74
Exec Oct 21 2025
Filed Oct 23 2025 · 4:06 PM ET SMMTPURCHASE Summit Therapeutics Inc. View filing → $5.9M
333,394 sh × $17.68
Exec Sep 10 2025
Filed Sep 11 2025 · 7:36 PM ET